

PHARMACY GNIPST BULLETIN

Volume-4, Issue-5



**GURU NANAK INSTITUTE OF PHARMACEUTICAL
SCIENCE AND TECHNOLOGY**

157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India

Contents

01 Message from Director and Principal

02 Recent Researches

03 New Drug Approvals

04 Clinical Trial News

05 Disease Outbreak News

06 Campus News

07 Special Page and Game time





MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my heartfelt greetings and warm wishes to all our students, faculty members, staff, alumni, and well-wishers on the auspicious occasion of Rabindra Jayanti.

Rabindra Jayanti is a celebration of the birth anniversary of the great poet, philosopher, Nobel Laureate, and cultural icon, Gurudev Rabindranath

Tagore, whose timeless contributions to literature, music, art, and education continue to inspire generations across the world. His vision of humanity, harmony, creativity, and universal brotherhood remains deeply relevant even today.

On this special occasion, let us remember and cherish the values and ideals propagated by Gurudev Tagore — the pursuit of knowledge, freedom of thought, respect for culture, and compassion for humanity. His works inspire us to nurture creativity, intellectual excellence, and social responsibility in our personal and professional lives.

At GNIPST, we believe in fostering not only academic excellence but also cultural awareness, ethical values, and holistic development among our students. Celebrating Rabindra Jayanti reminds us of the importance of preserving our rich cultural heritage while striving toward innovation and progress.

May the teachings and ideals of Rabindranath Tagore continue to guide us toward wisdom, unity, peace, and enlightenment.

Wishing everyone a meaningful and joyous Rabindra Jayanti.

Prof. (Dr.) Abhijit Sengupta

MESSAGE FROM HONORABLE PRINCIPAL

I extend my warm greetings and heartfelt best wishes to all our students, faculty members, staff, alumni, and valued partners on the auspicious occasion of Rabindra Jayanti.

Rabindra Jayanti commemorates the birth anniversary of the great poet, philosopher, Nobel Laureate, and cultural icon Gurudev Rabindranath Tagore. His timeless contributions to literature, music, art, and education continue to inspire generations and uphold the values of humanity, creativity, freedom of thought, and universal harmony.

At Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), we believe that education extends beyond academic excellence to encompass cultural values, social responsibility, and holistic development. Since our inception in 2005, GNIPST has emerged as a distinguished centre of pharmaceutical education, recognized by the Pharmacy Council of India (PCI), accredited by NAAC and NBA, and ranked 85th in NIRF 2025. Our continued commitment is to nurture competent, ethical, and socially responsible professionals who uphold the values of integrity, collaboration, and mutual respect.

On this special occasion, let us remember and reflect upon the ideals of Gurudev Rabindranath Tagore, whose vision continues to guide us toward intellectual growth, cultural enrichment, and humanistic values. May his teachings inspire us to cultivate creativity, knowledge, and a spirit of universal brotherhood within our academic community.

Let us celebrate Rabindra Jayanti with respect, reflection, and a renewed commitment to cultural heritage and academic excellence.

Wishing you all a meaningful and inspiring Rabindra Jayanti!

Prof. (Dr.) Lopamudra Datta





RECENT RESEARCHES



Infection prevention and control guideline for Ebola and Marburg diseases

MORE INFO

www.who.int/

This document provides public health advice on multisectoral actions to support the social and economic protection of communities affected by Ebola and Marburg disease outbreaks. These outbreaks pose significant health risks and have wide-ranging social and economic consequences, including disruption of services, livelihoods and social cohesion, as well as stigma and discrimination. The guidance is informed by operational experience, including the 2025 Ebola outbreak in the Democratic Republic of the Congo, and is aligned with WHO's health emergency preparedness, response and resilience framework.

The publication outlines approaches to community social protection, emphasizing coordinated multisectoral action to mitigate vulnerability and ensure equitable access to essential services. It describes practical steps for identifying vulnerable groups, assessing service disruptions and implementing integrated interventions across sectors such as health, social welfare, education, food security and mental health. The guidance highlights the importance of preparedness, community engagement and continuity of support throughout the emergency cycle, including recovery phases. It aims to strengthen outbreak response by addressing broader social determinants, protecting affected populations and enhancing resilience to future health emergencies.

Laboratory testing of Andes virus (Orthohantavirus andesense) infection: interim guidance

MORE INFO

<https://www.who.int/publications/item/B09765>

This document provides interim guidance for laboratories, clinicians, health workers, public health officials and other stakeholders responding to outbreaks of Andes virus in non-endemic areas (i.e. areas where ANDV is not enzootic in rodent reservoir) and involved in the diagnosis and care of patients with suspected or probable Andes virus, from specimen collection through to diagnostic analysis and reporting.

Dracunculiasis eradication: global surveillance summary, 2025

MORE INFO

<https://www.who.int/publications/item/who-wer10117-59-65>

D. medinensis transmission has now been reduced to historically low levels. It is encouraging that most countries have maintained zero-case incidence against a background of functioning surveillance systems and intensively-promoted incentive schemes for confirmed human cases and animal infections. However, eradication has proven more complex and required more years of programme activity than was originally anticipated. The target still feels some distance away. The persistence of sporadic human cases, transmission involving non-human mammalian definitive hosts, and re-emergence of transmission in areas that were previously believed to have achieved interruption all point to the need for sustained, high quality surveillance, rigorous epidemiological investigation and intensified interventions in identified foci, and renewed consideration of programme refinements and innovation.



FDA

NEW DRUG APPROVALS

Otarmeni (lunsotogene parvec-cwba) Suspension for Intracochlear Infusion

- Company: Regeneron Pharmaceuticals, Inc.
- Date of Approval: April 23, 2026
- Treatment for: Hearing Loss



Langlara (insulin glargine-aldy) Injection

- Company: Lannett Company, Inc.
- Date of Approval: April 29, 2026
- Treatment for: Diabetes, Type 1, Type 2 Diabetes



Veppanu (vepdegestrant) Tablets

- Company: Arvinas, Inc.
- Date of Approval: May 1, 2026
- Treatment for: Breast Cancer



Beqalzi (sonrotoclax) Tablets

- Company: BeOne Medicines Ltd.
- Date of Approval: May 13, 2026
- Treatment for: Mantle Cell Lymphoma



Trimbow (beclomethasone dipropionate, formoterol fumarate and glycopyrrolate) Inhalation Aerosol

- Company: Chiesi USA, Inc.
- Date of Approval: May 14, 2026
- Treatment for: Asthma, Maintenance



Immgolis Intri (golimumab-sldi) Injection

- Company: Accord BioPharma, Inc.
- Date of Approval: May 15, 2026
- Treatment for: Rheumatoid Arthritis



Immgolis (golimumab-sldi) Injection

- Company: Accord BioPharma, Inc.
- Date of Approval: May 15, 2026
- Treatment for: Rheumatoid Arthritis, Ulcerative Colitis



<https://www.drugs.com/newdrugs-archive/2025.html>



CLINICAL TRIAL NEWS



01.

Revolution Medicines Statement on FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer

May 1, 2026 - The U.S. Food and Drug Administration (FDA) has issued a “safe to proceed” letter to Revolution Medicines, allowing the company to initiate an expanded access treatment protocol (EAP) for daraxonrasib, an investigational RAS(ON) inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

02.

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

OSAKA, Japan and CAMBRIDGE, Massachusetts, May 4, 2026 - Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase].

03.

Johnson & Johnson Investigational Co-Antibody Therapy JNJ-4804 Shows Potential to Raise the Bar for Clinical Efficacy in Treating Refractory Inflammatory Bowel Disease

Chicago, Ill., (May 5, 2026) - Johnson & Johnson (NYSE: JNJ) today announced Phase 2b data from two studies evaluating JNJ-4804, an investigational co-antibody therapy targeting both interleukin-23 (IL-23) and tumor necrosis factor-alpha (TNF-α), in patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) that is refractory to systemic therapies.

04.

Viridian Therapeutics Announces Positive Topline Results from Elegrobarb Phase 3 REVEAL-2 Clinical Trial in Chronic Thyroid Eye Disease

WALTHAM, Mass.-(BUSINESS WIRE) May 5, 2026 - Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced positive topline data from the REVEAL-2 phase 3 clinical trial of elegrobarb in patients with chronic thyroid eye disease (TED).

05.

Oral Small-Molecule GLP-1 Drugs Penetrate Deep Into the Brain to Suppress Cravings

May 6, 2026 -- A National Institutes of Health (NIH)-funded study has found that an emerging class of GLP-1 weight-loss drugs suppress eating for pleasure, or hedonic feeding, in mice by modulating a reward circuit deep within the brain. This newly charted pathway — separate from previously described mechanisms that broadly affect appetite — could be an avenue by which GLP-1s treat other dysfunctions in reward processing, such as substance use disorder.

06.

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

RAHWAY, N.J.-(BUSINESS WIRE) May 7, 2026 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the large-scale synthesis of enlicitide decanoate, the company's investigational oral PCSK9 inhibitor, using a tailored suite of enzymes in the latest issue of the peer reviewed journal Science.

- Publication in Science magazine outlines blueprint for the scalable synthesis of complex orally available macrocyclic peptides

07.

Lilly's Foundayo and Lower-Dose Zepbound Helped People Maintain Weight Loss After Switching from Higher Doses of Injectable Incretin Therapy in Two Late-Phase Trials

INDIANAPOLIS, May 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.

MORE INFORMATION ➔

https://www.drugs.com/clinical_trials/praxis-precision-medicines-announces-fda-has-granted-breakthrough-therapy-designation-22271.html




DISEASE OUTBREAK NEWS (DONS)

Hantavirus cluster linked to cruise ship travel, Multi-country

13 May 2026

Situation at a glance

This is the third Disease Outbreak News report on the hantavirus cluster, following the notification to the World Health Organization (WHO) on 2 May 2026 of severe respiratory illness cases aboard MV Hondius, a cruise ship. Since the last DON was published on 8 May, two additional confirmed cases were reported from France and Spain. In addition, there is one inconclusive result for a case in the United States of America. All were passengers on the ship. As of 13 May, a total of 11 cases, including three deaths, have been reported (case fatality ratio 27%). Eight cases were laboratory-confirmed for Andes virus (ANDV) infection, two are probable, and one case remains inconclusive and undergoing further testing. Through the International Health Regulations (2005) (IHR) channels, National IHR Focal Points (NFPs) have all been informed and are supporting international contact tracing efforts. WHO has assessed the risk posed by this event to the global population as low and will continue to monitor the epidemiological situation and update the risk assessment as needed.



MORE INFO

<https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON601>

Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda

16 May 2026

Situation at a glance

On 5 May 2026, the World Health Organization (WHO) was alerted of a high-mortality outbreak of unknown illness in Mongbwalu Health Zone, Ituri Province, Democratic Republic of the Congo (DRC), including deaths among health workers. On 14 May 2026, the Institut national de recherche biomédicale (INRB) Kinshasa analyzed 13 blood samples from Rwampara Health Zone, Ituri Province. Laboratory analysis confirmed Bundibugyo virus disease (BVD) in eight of these samples on 15 May, a species of Ebola. The case fatality rates in the past two BVD outbreaks have ranged from 30% to 50%. Unlike Ebola virus disease, there is no licensed vaccine or specific therapeutics against Bundibugyo virus, though early supportive care is lifesaving. On 15 May 2026, the Ministry of Public Health, Hygiene and Social Welfare, DRC, officially declared the 17th Ebola Disease outbreak in DRC. Concurrently, the Uganda Ministry of Health confirmed an outbreak of BVD following the identification of one imported case from DRC, a Congolese man who died in the capital city of Kampala. On 16 May 2026, WHO Director-General, after having consulted the States Parties where the event is known to be currently occurring, determined that the Ebola disease caused by Bundibugyo virus in DRC and Uganda constitutes a public health emergency of international concern (PHEIC), as defined in the provisions of IHR. Response measures include deployment of rapid response teams, delivery of medical supplies, strengthened surveillance, laboratory confirmation, infection prevention and control assessments, the set-up of safe treatment centers, and community engagement.




MORE INFO

<https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON602>



CAMPUS NEWS




1. **Success Story:** The Heartiest congratulations to our students **Arin Dhan, Aratrika Kansabanik, Arko Kundu, Arnab Maity, Dibyendu Bera, Mridul Kumar Bej, Debalina Mondal, Partha Biswas, Sanjana Saha, Sayan Dutta, Santanu Ghosh, Soumalya Sasmal, Susmita Dinda, Tanusri Jana, Shubhodeep Pramanik** have been successfully selected for the position of “Pharmacist” at **MedPlus**. His dedication, hard work, and perseverance have truly paid off. Gnipst is very proud to see you achieve this milestone and wish you great success in your professional journey ahead.




2. **Success Story:** **Ayush Kumar Gupta** has been successfully placed at **Zifo** in the **R&D Department**, as **Associate Analyst**. His dedication, hard work, and perseverance have truly paid off. Gnipst is very proud to see you achieve this milestone and wish you great success in your professional journey ahead.

3. **Success Story:** **Nafisha Shafkat** has been successfully selected for the position at **Abbott Healthcare**. His dedication, hard work, and perseverance have truly paid off. Gnipst is very proud to see you achieve this milestone and wish you great success in your professional journey ahead.



GNIPST GAME TIME



Puzzle 1:



Puzzle 2:



Stay tuned for to the next edition for a shout out to fastest correct answers!

Submit your answer



SCAN
ME

or

CLICK
HERE

Celebrating the Achievers!




Shreya Mondal
B. Pharm, 6th Semester

Guru Nanak Institute of Pharmaceutical Science and Technology

Honoring a Legacy:

Pochishe Baishakh 2026



Pochishe Baishakh marks the 165th birth anniversary of the legendary polymath, Rabindranath Tagore, observed on May 9, 2026. Falling on the 25th day of the Bengali month of Baishakh, this occasion holds immense cultural and emotional significance for Bengalis across the globe. Tagore, Asia's first Nobel laureate, reshaped Bengali literature, music, and art, leaving behind an immortal legacy that continues to define the region's cultural identity.

The day is celebrated with deep reverence through Rabindra Sangeet (Tagore's songs) recitals, poetry readings, dance dramas, and cultural gatherings at schools, universities, and community centers, particularly in West Bengal and Bangladesh. Beyond mere nostalgia, Pochishe Baishakh serves as an annual reminder of Tagore's timeless philosophies on humanism, universalism, and freedom, offering a moment of collective introspection and creative renewal for generations old and new.

Editor- in- Chief

Prof. (Dr.) Abhijit Sengupta

Managing Editors

Prof. (Dr.) Lopamudra Datta

Associate Editors

Mr. Tushar Adhikari
Ms. Manjarima Ganguli

Editorial Board Members

Mrs. Indrani Banerjee Chakraborty
Ms. Parnasree Chakraborty
Ms. Lopamudra Saha
Mr. Sarthak Saha



COURSES OFFERED

PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major
Recruiters



**Latest
news**



www.gnipst.ac.in



www.facebook.com



www.linkedin.com



api.whatsapp.com

